BP 2.94, or BP-294, also known as FUB-94, is a histamine H<sub>3</sub> receptor agonist which was under development for the treatment of asthma, inflammation, pain, and peptic ulcers but was never marketed. It is taken orally.
The drug functions as an orally active prodrug of (R)-ñ-methylhistamine, which in turn acts as a potent and selective agonist of the histamine H<sub>3</sub> receptor. BP 2.94 has shown anti-inflammatory, antinociceptive, gastric anti-secretory, and sedative and hypnotic effects in animals. It has been found to increase slow wave sleep in animals, including dramatically so in cats.
BP 2.94 was under development by Bioprojet. It reached phase 2 clinical trials prior to the discontinuation of its development.